Zymeworks Inc. (ZYME) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. This is the conference operator. Welcome to the ZineWorks third quarter 2025 results conference call and webcast. As a reminder, all participants are in a listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To ask a question, press star 11 on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star and then zero. I would now like to turn the conference over to Sarah Nell Inamander, Senior Director of Investor Relations. Please go ahead. Thank you, operator, and good afternoon, everyone. Thank you for joining our third quarter 2025 results conference call. As usual, before we begin, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For discussion of these risks and uncertainties, we refer you to our latest STC filings as found on our website and as filed with the STC. In a moment, I will hand over to Leonie Patterson, our Executive Vice President and Chief Business and Financial Officer, who will provide an overview of our recent business and partnership updates, along with financial results for our third quarter 2025. Following this, Dr. Sabina Mikan, our Senior Vice President of Clinical Development, will provide progress updates on our phase one programs, CW191 and CW251. We will then pass the call over to Dr. Pa...